Supernus Pharmaceuticals (NASDAQ:SUPN) Research Coverage Started at Bank of America

Bank of America assumed coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report report published on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $47.00 price objective on the specialty pharmaceutical company’s stock.

Other analysts have also issued reports about the stock. Jefferies Financial Group began coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, November 4th. They set a “strong-buy” rating for the company. Piper Sandler began coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, November 4th. They issued an “overweight” rating and a $47.00 price objective on the stock. Weiss Ratings downgraded shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Finally, Zacks Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.20.

Supernus Pharmaceuticals Trading Up 2.4%

SUPN opened at $29.45 on Monday. The firm has a market cap of $3.48 billion, a price-to-earnings ratio of 8.23, a PEG ratio of 0.58 and a beta of 0.84. Supernus Pharmaceuticals has a 12 month low of $25.92 and a 12 month high of $42.81. The stock has a fifty day moving average price of $40.10 and a 200-day moving average price of $46.50.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). Supernus Pharmaceuticals had a net margin of 32.75% and a negative return on equity of 418.04%. The company had revenue of $208.60 million for the quarter, compared to the consensus estimate of $217.56 million. During the same period in the previous year, the business earned ($0.80) EPS. Supernus Pharmaceuticals’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, equities research analysts forecast that Supernus Pharmaceuticals will post 3.80 EPS for the current year.

Supernus Pharmaceuticals Announces Dividend

The firm also recently announced a special dividend, which was paid on Friday, November 6th. Investors of record on Friday, October 30th were given a dividend of $8.13 per share.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in SUPN. Public Employees Retirement System of Ohio purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $25,000. Heritage Family Offices LLP purchased a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Rockefeller Capital Management L.P. boosted its stake in Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter worth approximately $64,000. Finally, Versant Capital Management Inc boosted its stake in Supernus Pharmaceuticals by 47.2% in the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock worth $65,000 after purchasing an additional 482 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease. The company’s marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson’s disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson’s disease.